Denosumab is an antibody that blocks the RANK ligand, a protein that tells the body to remove bone.
Denosumab is the best chance for replacing the sales those competitors may steal.
Same chemical (denosumab), at different doses, and Xgeva was actually approved more recently.
FORBES: Amgen's Earnings Beat Shows Death Of Mass-Market Drugs
At Amgen, Perlmutter had some success, most notably with the bone drug denosumab, which in two different formulations is becoming a blockbuster.
FORBES: In Bold, Smart Move, Merck Makes Roger Perlmutter Its Research Chief, Jettisoning Peter Kim
Cowen warn against comparing denosumab data to the results for other drugs.
For denosumab to succeed, Amgen will have to battle with Novartis and its once-a-year osteoporosis infusion, Reclast, and Merck, which is racing toward the market with its own first-of-its-kind osteoporosis pill.
Amgen Chief Executive KevinSharerKevin Sharer has hopes that a new drug, denosumab, could become a "double blockbuster, " both as a twice-a-year treatment for osteoporosis and as a remedy for cancers of the bone.
Amgen Chief Executive Kevin Sharer has hopes that a new drug, denosumab, could become a "double blockbuster, " both as a twice-a-year treatment for osteoporosis and as a remedy for cancers of the bone.
The biotechnology firm announced that a much-awaited study of its bone drug Xgeva (also known as denosumab, and sold for osteoporosis as Prolia) prevented prostate cancer from spreading to the bone in patient whose levels of prostate-specific antigen are rising.
FORBES: Amgen Drug Prevents Prostate Cancer From Spreading To Bone
For denosumab to succeed, Amgen will have to battle with Novartis (nyse: NVS - news - people ) and its once-a-year osteoporosis infusion, Reclast, and Merck (nyse: MRK - news - people ), which is racing toward the market with its own first-of-its-kind osteoporosis pill.
应用推荐